April 30, 2025 03:42 PM EDT

BeiGene scores a win from US Patent Office in spat over Brukinsa

Nicole DeFeudis

Editor

A tribunal within the US Patent and Trademark Office invalidated several claims of a patent held by AbbVie’s Pharmacyclics, marking a key win for its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BeiGene scores a win from US Patent Office in spat over Brukinsa

Nicole DeFeudis

Editor

Sign up to read this article for free.

Exits continue at FDA, as more staff in drug office follow fired colleagues out the door

Updated: Novartis to buy Regulus Therapeutics for up to $1.7B

FDA delays PDUFA date for small biotech, raising questions about impact of agency cuts

FDA approves J&J's rare disease drug that's expected to compete with argenx and UCB

The Endpoints Slack interview: Arc Institute's Patrick Hsu on investing, AI and new ways of research

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

BeiGene scores a win from US Patent Of­fice in spat over Brukin­sa

Nicole DeFeudis

Editor

Sign up to read this article for free.

Ex­its con­tin­ue at FDA, as more staff in drug of­fice fol­low fired col­leagues out the door

Up­dat­ed: No­var­tis to buy Reg­u­lus Ther­a­peu­tics for up to $1.7B

FDA de­lays PDU­FA date for small biotech, rais­ing ques­tions about im­pact of agency cuts

FDA ap­proves J&J's rare dis­ease drug that's ex­pect­ed to com­pete with ar­genx and UCB

The End­points Slack in­ter­view: Arc In­sti­tute's Patrick Hsu on in­vest­ing, AI and new ways of re­search

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

BeiGene scores a win from US Patent Office in spat over Brukinsa

Exits continue at FDA, as more staff in drug office follow fired colleagues out the door

Updated: Novartis to buy Regulus Therapeutics for up to $1.7B

FDA delays PDUFA date for small biotech, raising questions about impact of agency cuts

FDA approves J&J's rare disease drug that's expected to compete with argenx and UCB

The Endpoints Slack interview: Arc Institute's Patrick Hsu on investing, AI and new ways of research

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?